The US Food and Drug Administration (FDA) will convene a panel of outside advisers in July to review whether seven unapproved peptide injections — compounds marketed online as treatments for injuries, inflammation, and ageing — should be made available through compounding pharmacies. The move follows repeated calls by Health Secretary Robert F. Kennedy Jr., who has publicly endorsed peptides and claims personal benefit from their use, to ease regulations on the substances. Critics, including former FDA official Dr. Peter Lurie, warn that bypassing standard clinical testing sets a dangerous precedent, with one describing it as a "profound threat" to the agency's drug-vetting system; the FDA itself previously classified many of the same peptides as high-risk, citing potential links to cancer and organ damage.